Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

A French pharmaceutical giant is acquiring a Cambridge, Mass. biotech and its rare immunology disease treatment which is ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

Sanofi will purchase Blueprint Medicines for $129 per share in cash, with additional non-tradable contingent value rights (CVRs) of up to $6 per share tied to the development and regulatory ...

On Wednesday, Citi analysts upgraded Blueprint Medicines (NASDAQ:BPMC) stock to Neutral from a previous rating, following the announcement of its acquisition by Sanofi (NASDAQ:SNY). The ...

On Tuesday, Citizens JMP analysts downgraded Blueprint Medicines stock (NASDAQ: NASDAQ:BPMC) from Market Outperform to Market Perform. This change follows the announcement of a proposed acquisition by ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.